Importantly, Xolair is not a replacement for epinephrine injections — namely, EpiPen devices, which are used to reverse a life-threatening, body-wide allergic reaction called anaphylaxis.

Joshua Cohen is a Boston-based writer who covers health policy. Two weeks ago, the Food and Drug Administration approved Xolair (omalizumab) for immunoglobulin E-mediated food allergy in certain ...

Varner was only able to stay on the medication using Social Security disability support. She said if she didn’t have ...

Xolair (omalizumab) generated revenues of more ... which is available in markets in the US and EU as a subcutaneous injection lasting a few minutes, instead of a lengthy infusion.

The approved dose is 300 mg by subcutaneous injection every four weeks. "The EU approval of Xolair in CSU is truly exciting for patients with this chronic and debilitating skin disease," said ...